Related Experiment Videos
Psychiatric adverse events during vigabatrin therapy
1Department of Psychiatry, MCP Hahnemann University, Philadelphia, PA, USA.
Neurology
|October 26, 1999
Summary
Vigabatrin therapy for epilepsy increases the risk of depression and psychosis. These psychiatric adverse events, though manageable with dose reduction or other treatments, warrant careful monitoring in patients.
Area of Science:
- Neurology
- Psychiatry
- Pharmacology
Background:
- Vigabatrin is an antiepileptic drug used for treatment-refractory partial epilepsy.
- Psychiatric adverse events are a concern with vigabatrin therapy.
Purpose of the Study:
- To determine the incidence of psychiatric adverse events associated with vigabatrin therapy.
- To analyze rates of depression and psychosis in patients receiving vigabatrin compared to placebo.
Main Methods:
- Review of data from double-blind, placebo-controlled trials.
- Standardized adverse event terms were used for analysis.
- Incidence rates of psychiatric events were compared between vigabatrin and placebo groups.
Main Results:
- Vigabatrin significantly increased the incidence of depression (12.1% vs. 3.5%) and psychosis (2.5% vs. 0.3%) compared to placebo.
- No significant differences were observed for aggression, mania, agitation, emotional lability, anxiety, or suicide attempts.
- Psychosis was generally transient and responsive to treatment adjustments; depression was typically mild.
Conclusions:
- Vigabatrin use is associated with an increased occurrence of depression and psychosis in epilepsy patients.
- The frequency of psychosis may be lower than previously reported.
- These adverse events appear manageable with dose reduction or psychotropic treatment.